An SGLT2 inhibitor and active metabolite of sergliflozin etabonate
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Sergliflozin A

Item No. 14342

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
2[(4methoxyphenyl)methyl]phenyl, β-D-glucopyranoside
CAS Number
360775-96-8
Molecular Formula
C20H24O7
Formula Weight
376.4
Purity
≥98%
Formulation
A solid
Solubility(Learn about Variance in Solubility)
Acetonitrile: Slightly Soluble: 0.1-1 mg/mlDMSO: Sparingly Soluble: 1-10 mg/ml
SMILES
O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC2=C(CC3=CC=C(OC)C=C3)C=CC=C2
InChi Code
InChI=1S/C20H24O7/c1-25-14-8-6-12(7-9-14)10-13-4-2-3-5-15(13)26-20-19(24)18(23)17(22)16(11-21)27-20/h2-9,16-24H,10-11H2,1H3/t16-,17-,18+,19-,20-/m1/s1
InChi Key
HFLCZNNDZKKXCS-OUUBHVDSSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $54

    Add

    5 mg

    $257

    Add

    10 mg

    $486

    Add
    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    Sergliflozin A is an inhibitor of sodium-glucose cotransporter 2 (SGLT2; Ki = 2.39 nM for the human transporter) and an active metabolite of sergliflozin etabonate.1 It is formed from sergliflozin etabonate by esterases and selectively inhibits SGLT2 over SGLT1 (Ki = 708 nM for the human transporter). Co-infusion of sergliflozin A and glucose reduces maximal renal glucose reabsorption rates in rats.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Katsuno, K., Fujimori, Y., Takemura, Y., et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J. Pharmacol. Exp. Ther. 320(1), 323-330 (2007).